Jazz Pharmaceuticals (JAZZ) 175.42 $JAZZ
Suitors allegedly eyeing Italian pharma firm's rare diseases unit
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 12:03PM CDT
SHPG: 241.98 (+1.01), JAZZ: 175.42 (unch)
Insider Trading Alert - KCG, RSE And JAZZ Traded By Insiders
at The Street - Mon Mar 30, 10:15AM CDT
Stocks with insider trader activity include KCG, RSE and JAZZ
KCG: 12.33 (-0.11), JAZZ: 175.42 (unch), RSE: 18.99 (-0.11)
InsiderInsights.com Daily Round Up 3/27/15: COCP, GPRO, SJW, AGCO
InsiderInsights - at Seeking Alpha - Sun Mar 29, 12:55PM CDT
GPRO: 43.58 (+0.88), HCOM: 26.39 (+0.07), DPLO: 34.54 (+0.82), AGCO: 48.07 (+1.24), ENV: 56.91 (+0.87), LPI: 13.21 (+0.46), GOOG: 552.03 (+3.69), NOW: 79.44 (+0.97), ARMK: 32.10 (+0.53), JAZZ: 175.42 (unch), GLF: 13.45 (-0.10), SJW: 30.95 (+0.86), JGW: 9.98 (-0.02), ALCO: 52.72 (+1.68), FI: 18.80 (+1.08), CRM: 66.85 (+0.30)
Insider Weekends - March 27, 2015
Asif Suria - at Seeking Alpha - Sun Mar 29, 1:46AM CDT
Welcome to edition 249 of Insider Weekends. Insider buying declined sharply last week with insiders buying $27.48 million of stock compared to $148.24 million in the week prior. Selling also decreased with insiders selling $1.37 billion of stock last...
PN: 13.07 (-0.32), FEYE: 40.03 (+0.22), MMI: 37.09 (+0.56), OPK: 14.71 (+0.22), JAZZ: 175.42 (unch), PHII: 30.50 (-0.65), SLG: 129.55 (+1.81), SJW: 30.95 (+0.86), ROST: 105.74 (+1.61), FI: 18.80 (+1.08)
Marine Biotechnology - Global Strategic Business Report 2015-2020: A Science to Address Global Challenges
M2 - Thu Mar 26, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hcgcbk/marine) has announced the addition of the "Marine Biotechnology - Global Strategic Business Report" report to their offering. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Marine Biotechnology in US$ Million. The Global market is further analyzed by the following Product Segments: Marine Biomaterials, Marine Bioactive Substances, and Others. The Major End-Use Applications analyzed are Industrial Products, Health Care/Biotechnology, Consumer Products, Public Services & Infrastructure, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. The report profiles 84 companies including many key and niche players such as: - Aker BioMarine AS (Norway) - Aqua Bio Technology ASA (Norway) - BASF SE (Germany) - CP Kelco (US) - Cyanotech Corp. (US) - Nutrex Hawaii (US) - FMC Health and Nutrition (US) - NovaMatrix (Norway) - GlycoMar Ltd. (UK) - Jazz Pharmaceuticals plc (Ireland) - Lonza Group Ltd. (Switzerland) - Marinova Pty Ltd (Australia) - New England Biolabs Inc (US) - oceanBASIS GmbH (Germany) - PharmaMar S.A (Spain) - PML Applications Ltd. (UK) - Prolume Ltd (US) - BioLume?, Inc. (US) - Royal DSM N.V (Netherlands) - Sea Run Holdings, Inc. (US) - SEPPIC (France) - Biotech Marine (France) - Tequesta BioVentures (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. A REVIEW OF END-USE MARKETS/ APPLICATIONS 3. R&D ACTIVITY IN MARINE BIOTECHNOLOGY - A REVIEW 4. MARINE BIOTECHNOLOGY - AN OVERVIEW 5. KEY RESEARCH FINDINGS ON MARINE ORGANISMS 6. PRODUCT INTRODUCTIONS/INNOVATIONS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 84 (including Divisions/Subsidiaries - 89) - The United States (25) - Canada (1) - Japan (2) - Europe (44) - - France (4) - - Germany (4) - - The United Kingdom (4) - - Spain (2) - - Rest of Europe (30) - Asia-Pacific (Excluding Japan) (15) - Latin America (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/hcgcbk/marine
CYAN: 8.60 (+0.06), JAZZ: 175.42 (unch)
Watch for Jazz Pharmaceuticals to Potentially Rebound After Falling 3.62% Yesterday
Comtex SmarTrend(R) - Mon Mar 23, 4:41PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $181.64 to a high of $188.21. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $182.60 on volume of 873,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 175.42 (unch)
Insider Trading Alert - CTSH, VNTV And JAZZ Traded By Insiders
at The Street - Mon Mar 23, 10:30AM CDT
Stocks with insider trader activity include CTSH, VNTV and JAZZ
JAZZ: 175.42 (unch), VNTV: 37.60 (+0.45), CTSH: 63.34 (+0.34)
EUSA Pharma Successfully Launches as an Independent Profitable Pharmaceutical Business with Global Reach and a Portfolio of Specialty Products Acquired from Jazz Pharmaceuticals
PR Newswire - Mon Mar 23, 4:00AM CDT
EUSA Pharma (EUSA), a newly-established profitable specialty pharmaceutical business with global reach, today announced its official launch following the acquisition of five approved specialty hospital products, a multi-national commercial infrastructure and the EUSA Pharma brand name from Jazz Pharmaceuticals plc (Jazz). The new company is led by Chief Executive Bryan Morton, who has over 30 years' healthcare industry experience and previously founded two specialty pharmaceutical companies including the original EUSA Pharma business that was acquired by Jazz in 2012. The newly-established EUSA is supported by significant funding raised from leading healthcare growth equity investor Essex Woodlands, and the company has ambitious plans to accelerate its growth through acquisition and in-licensing.
JAZZ: 175.42 (unch)
InsiderInsights.com Daily Round Up 3/20/15: DRRX, RWC, GEF.B, MRD
InsiderInsights - at Seeking Alpha - Sat Mar 21, 2:29AM CDT
NPBC: 10.84 (+0.14), HCOM: 26.39 (+0.07), DRII: 33.48 (+0.38), LGIH: 16.69 (+0.65), MRD: 17.75 (+0.63), STKL: 10.25 (-0.34), DRRX: 2.00 (+0.12), GOOG: 552.03 (+3.69), WSTC: 32.83 (+0.39), NLY: 10.45 (-0.08), PDVW: 49.99 (+1.65), GMED: 24.86 (+0.28), MHK: 184.72 (+3.50), NERV: 5.08 (-0.21), JAZZ: 175.42 (unch), RWC: 6.10 (+0.02), GOOGL: 561.13 (+3.58), ROST: 105.74 (+1.61)
Jazz Pharma Isn't Just Narcolepsy-Drug Maker
at Investor's Business Daily - Fri Mar 20, 5:24PM CDT
Jazz Pharmaceuticals (JAZZ) has made its mark as the provider of Xyrem, a drug for the sleep disorder narcolepsy. Jazz may be less known for being among the companies fighting cancer. Its Erwinaze is a treatment for acute lymphoblastic leukemia,...
JAZZ: 175.42 (unch)
This Drugmaker Stock Is Attempting A Re-Breakout
at Investor's Business Daily - Wed Mar 18, 7:02AM CDT
If at first you don't succeed, try, try again. Today's Young Guns Screen of the Day, which groups top-rated stocks that went public less than 15 years ago, features one particular pharmaceutical stock that is nearing a second breakout. Jazz...
VRX: 201.38 (+3.54), JAZZ: 175.42 (unch), SLXP: 172.65 (+0.05), HZNP: 25.78 (+3.97)
Watch for Jazz Pharmaceuticals to Potentially Pullback After Gaining 1.89% Yesterday
Comtex SmarTrend(R) - Tue Mar 17, 4:20PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $178.15 to a high of $183.38. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $180.00 on volume of 733,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JAZZ: 175.42 (unch)
Jazz Pharmaceuticals (JAZZ) Upgraded From Hold to Buy
at The Street - Thu Mar 05, 10:40AM CST
Jazz Pharmaceuticals (JAZZ) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
JAZZ: 175.42 (unch)
Jazz Pharmaceuticals Up on U.S. Approval of Xyrem REMS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 3:20PM CST
Jazz Pharmaceuticals' (JAZZ) shares gained 3.7% after FDA's notice.
CYTK: 7.10 (-0.06), JAZZ: 175.42 (unch), HZNP: 25.78 (+3.97), AFFX: 12.86 (+0.15)
Pfizer Inc. Has a Growth Problem -- Here Are 3 Ways to Change That
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 04, 7:02AM CST
Source: Pfizer, Facebook. Pfizer might be the largest pharmaceutical products company in the world by revenue, but it looks far from a force to be reckoned with at the moment. Pfizer's problems in a nutshell Like much of the big...
ISIS: 64.81 (+1.44), JAZZ: 175.42 (unch), AZN: 69.94 (-0.13), PFE: 35.00 (+0.47)
Jazz Pharmaceuticals Is Undervalued
Clinically Sound Investor - at Seeking Alpha - Mon Mar 02, 3:14PM CST
JAZZ: 175.42 (unch)
4 Big-Volume Stocks to Trade for Breakouts: La Jolla Pharma and More
at The Street - Mon Mar 02, 12:18PM CST
These stocks rising on unusual volume are within range of triggering breakout trades.
CUK: 48.73 (+0.60), LJPC: 19.13 (+0.10), JAZZ: 175.42 (unch), IMKTA: 49.81 (+1.73)
Splunk Shoots Up After Hours; Monster Beverage Also Up
at Investor's Business Daily - Thu Feb 26, 3:54PM CST
Stocks wavered to a split finish amid mixed economic data and more earnings reports. Splunk (SPLK) and Monster Beverage (MNST) were active in extended trading following their latest quarterly results. Software maker Splunk jumped nearly 9% after...
MNST: 140.44 (+2.45), AKRX: 48.08 (-0.40), JAZZ: 175.42 (unch), SPLK: 60.11 (-0.29), AAPL: 126.37 (+3.12)
Jazz Pharmaceuticals Tops Q4 Earnings And Tests Buy Point
at Investor's Business Daily - Thu Feb 26, 10:51AM CST
Jazz Pharmaceuticals (JAZZ), which develops treatments in the areas of narcolepsy, oncology, pain and psychiatry, topped Q4 earnings after the close Tuesday and broke out Wednesday. That came on the heels of a big move by fellow drugmaker Valeant...
VRX: 201.38 (+3.54), JAZZ: 175.42 (unch), SLXP: 172.65 (+0.05)
Company News for February 26, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Feb 26, 9:10AM CST
Companies in the News are: CHK,FSLR,JAZZ,TGT
FSLR: 60.69 (+1.08), CHK: 13.97 (-0.06), JAZZ: 175.42 (unch), TGT: 82.14 (+0.58)
Suitors allegedly eyeing Italian pharma firm's rare diseases unit
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 12:03PM CDT
SHPG: 241.98 (+1.01), JAZZ: 175.42 (unch)
Insider Trading Alert - KCG, RSE And JAZZ Traded By Insiders
at The Street - Mon Mar 30, 10:15AM CDT
Stocks with insider trader activity include KCG, RSE and JAZZ
KCG: 12.33 (-0.11), JAZZ: 175.42 (unch), RSE: 18.99 (-0.11)
InsiderInsights.com Daily Round Up 3/27/15: COCP, GPRO, SJW, AGCO
InsiderInsights - at Seeking Alpha - Sun Mar 29, 12:55PM CDT
GPRO: 43.58 (+0.88), HCOM: 26.39 (+0.07), DPLO: 34.54 (+0.82), AGCO: 48.07 (+1.24), ENV: 56.91 (+0.87), LPI: 13.21 (+0.46), GOOG: 552.03 (+3.69), NOW: 79.44 (+0.97), ARMK: 32.10 (+0.53), JAZZ: 175.42 (unch), GLF: 13.45 (-0.10), SJW: 30.95 (+0.86), JGW: 9.98 (-0.02), ALCO: 52.72 (+1.68), FI: 18.80 (+1.08), CRM: 66.85 (+0.30)
Insider Weekends - March 27, 2015
Asif Suria - at Seeking Alpha - Sun Mar 29, 1:46AM CDT
Welcome to edition 249 of Insider Weekends. Insider buying declined sharply last week with insiders buying $27.48 million of stock compared to $148.24 million in the week prior. Selling also decreased with insiders selling $1.37 billion of stock last...
PN: 13.07 (-0.32), FEYE: 40.03 (+0.22), MMI: 37.09 (+0.56), OPK: 14.71 (+0.22), JAZZ: 175.42 (unch), PHII: 30.50 (-0.65), SLG: 129.55 (+1.81), SJW: 30.95 (+0.86), ROST: 105.74 (+1.61), FI: 18.80 (+1.08)
Marine Biotechnology - Global Strategic Business Report 2015-2020: A Science to Address Global Challenges
M2 - Thu Mar 26, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hcgcbk/marine) has announced the addition of the "Marine Biotechnology - Global Strategic Business Report" report to their offering. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Marine Biotechnology in US$ Million. The Global market is further analyzed by the following Product Segments: Marine Biomaterials, Marine Bioactive Substances, and Others. The Major End-Use Applications analyzed are Industrial Products, Health Care/Biotechnology, Consumer Products, Public Services & Infrastructure, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. The report profiles 84 companies including many key and niche players such as: - Aker BioMarine AS (Norway) - Aqua Bio Technology ASA (Norway) - BASF SE (Germany) - CP Kelco (US) - Cyanotech Corp. (US) - Nutrex Hawaii (US) - FMC Health and Nutrition (US) - NovaMatrix (Norway) - GlycoMar Ltd. (UK) - Jazz Pharmaceuticals plc (Ireland) - Lonza Group Ltd. (Switzerland) - Marinova Pty Ltd (Australia) - New England Biolabs Inc (US) - oceanBASIS GmbH (Germany) - PharmaMar S.A (Spain) - PML Applications Ltd. (UK) - Prolume Ltd (US) - BioLume?, Inc. (US) - Royal DSM N.V (Netherlands) - Sea Run Holdings, Inc. (US) - SEPPIC (France) - Biotech Marine (France) - Tequesta BioVentures (US) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. A REVIEW OF END-USE MARKETS/ APPLICATIONS 3. R&D ACTIVITY IN MARINE BIOTECHNOLOGY - A REVIEW 4. MARINE BIOTECHNOLOGY - AN OVERVIEW 5. KEY RESEARCH FINDINGS ON MARINE ORGANISMS 6. PRODUCT INTRODUCTIONS/INNOVATIONS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 84 (including Divisions/Subsidiaries - 89) - The United States (25) - Canada (1) - Japan (2) - Europe (44) - - France (4) - - Germany (4) - - The United Kingdom (4) - - Spain (2) - - Rest of Europe (30) - Asia-Pacific (Excluding Japan) (15) - Latin America (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/hcgcbk/marine
CYAN: 8.60 (+0.06), JAZZ: 175.42 (unch)
Watch for Jazz Pharmaceuticals to Potentially Rebound After Falling 3.62% Yesterday
Comtex SmarTrend(R) - Mon Mar 23, 4:41PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $181.64 to a high of $188.21. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $182.60 on volume of 873,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JAZZ: 175.42 (unch)
Insider Trading Alert - CTSH, VNTV And JAZZ Traded By Insiders
at The Street - Mon Mar 23, 10:30AM CDT
Stocks with insider trader activity include CTSH, VNTV and JAZZ
JAZZ: 175.42 (unch), VNTV: 37.60 (+0.45), CTSH: 63.34 (+0.34)
EUSA Pharma Successfully Launches as an Independent Profitable Pharmaceutical Business with Global Reach and a Portfolio of Specialty Products Acquired from Jazz Pharmaceuticals
PR Newswire - Mon Mar 23, 4:00AM CDT
EUSA Pharma (EUSA), a newly-established profitable specialty pharmaceutical business with global reach, today announced its official launch following the acquisition of five approved specialty hospital products, a multi-national commercial infrastructure and the EUSA Pharma brand name from Jazz Pharmaceuticals plc (Jazz). The new company is led by Chief Executive Bryan Morton, who has over 30 years' healthcare industry experience and previously founded two specialty pharmaceutical companies including the original EUSA Pharma business that was acquired by Jazz in 2012. The newly-established EUSA is supported by significant funding raised from leading healthcare growth equity investor Essex Woodlands, and the company has ambitious plans to accelerate its growth through acquisition and in-licensing.
JAZZ: 175.42 (unch)
InsiderInsights.com Daily Round Up 3/20/15: DRRX, RWC, GEF.B, MRD
InsiderInsights - at Seeking Alpha - Sat Mar 21, 2:29AM CDT
NPBC: 10.84 (+0.14), HCOM: 26.39 (+0.07), DRII: 33.48 (+0.38), LGIH: 16.69 (+0.65), MRD: 17.75 (+0.63), STKL: 10.25 (-0.34), DRRX: 2.00 (+0.12), GOOG: 552.03 (+3.69), WSTC: 32.83 (+0.39), NLY: 10.45 (-0.08), PDVW: 49.99 (+1.65), GMED: 24.86 (+0.28), MHK: 184.72 (+3.50), NERV: 5.08 (-0.21), JAZZ: 175.42 (unch), RWC: 6.10 (+0.02), GOOGL: 561.13 (+3.58), ROST: 105.74 (+1.61)
Jazz Pharma Isn't Just Narcolepsy-Drug Maker
at Investor's Business Daily - Fri Mar 20, 5:24PM CDT
Jazz Pharmaceuticals (JAZZ) has made its mark as the provider of Xyrem, a drug for the sleep disorder narcolepsy. Jazz may be less known for being among the companies fighting cancer. Its Erwinaze is a treatment for acute lymphoblastic leukemia,...
JAZZ: 175.42 (unch)
This Drugmaker Stock Is Attempting A Re-Breakout
at Investor's Business Daily - Wed Mar 18, 7:02AM CDT
If at first you don't succeed, try, try again. Today's Young Guns Screen of the Day, which groups top-rated stocks that went public less than 15 years ago, features one particular pharmaceutical stock that is nearing a second breakout. Jazz...
VRX: 201.38 (+3.54), JAZZ: 175.42 (unch), SLXP: 172.65 (+0.05), HZNP: 25.78 (+3.97)
Watch for Jazz Pharmaceuticals to Potentially Pullback After Gaining 1.89% Yesterday
Comtex SmarTrend(R) - Tue Mar 17, 4:20PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $178.15 to a high of $183.38. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $180.00 on volume of 733,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
JAZZ: 175.42 (unch)
Jazz Pharmaceuticals (JAZZ) Upgraded From Hold to Buy
at The Street - Thu Mar 05, 10:40AM CST
Jazz Pharmaceuticals (JAZZ) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
JAZZ: 175.42 (unch)
Jazz Pharmaceuticals Up on U.S. Approval of Xyrem REMS - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 3:20PM CST
Jazz Pharmaceuticals' (JAZZ) shares gained 3.7% after FDA's notice.
CYTK: 7.10 (-0.06), JAZZ: 175.42 (unch), HZNP: 25.78 (+3.97), AFFX: 12.86 (+0.15)
Pfizer Inc. Has a Growth Problem -- Here Are 3 Ways to Change That
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 04, 7:02AM CST
Source: Pfizer, Facebook. Pfizer might be the largest pharmaceutical products company in the world by revenue, but it looks far from a force to be reckoned with at the moment. Pfizer's problems in a nutshell Like much of the big...
ISIS: 64.81 (+1.44), JAZZ: 175.42 (unch), AZN: 69.94 (-0.13), PFE: 35.00 (+0.47)
Jazz Pharmaceuticals Is Undervalued
Clinically Sound Investor - at Seeking Alpha - Mon Mar 02, 3:14PM CST
JAZZ: 175.42 (unch)
4 Big-Volume Stocks to Trade for Breakouts: La Jolla Pharma and More
at The Street - Mon Mar 02, 12:18PM CST
These stocks rising on unusual volume are within range of triggering breakout trades.
CUK: 48.73 (+0.60), LJPC: 19.13 (+0.10), JAZZ: 175.42 (unch), IMKTA: 49.81 (+1.73)
Splunk Shoots Up After Hours; Monster Beverage Also Up
at Investor's Business Daily - Thu Feb 26, 3:54PM CST
Stocks wavered to a split finish amid mixed economic data and more earnings reports. Splunk (SPLK) and Monster Beverage (MNST) were active in extended trading following their latest quarterly results. Software maker Splunk jumped nearly 9% after...
MNST: 140.44 (+2.45), AKRX: 48.08 (-0.40), JAZZ: 175.42 (unch), SPLK: 60.11 (-0.29), AAPL: 126.37 (+3.12)
Jazz Pharmaceuticals Tops Q4 Earnings And Tests Buy Point
at Investor's Business Daily - Thu Feb 26, 10:51AM CST
Jazz Pharmaceuticals (JAZZ), which develops treatments in the areas of narcolepsy, oncology, pain and psychiatry, topped Q4 earnings after the close Tuesday and broke out Wednesday. That came on the heels of a big move by fellow drugmaker Valeant...
VRX: 201.38 (+3.54), JAZZ: 175.42 (unch), SLXP: 172.65 (+0.05)
Company News for February 26, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Feb 26, 9:10AM CST
Companies in the News are: CHK,FSLR,JAZZ,TGT
FSLR: 60.69 (+1.08), CHK: 13.97 (-0.06), JAZZ: 175.42 (unch), TGT: 82.14 (+0.58)
